ALIX antibody | 3A9
ALIX was first reported to play a role in apoptosis dependent on its association with PDCD6 (Mahul-Mellier et al. 2006) but has subsequently shown to be involved in endocytosis (Matsuo et al. 2004), viral budding (Irie et al. 2008) and actin cytoskeletal assembly (Pan et al. 2006).
Mouse anti Alix, clone 3A9 has been used extensively for the detection of ALIX by Western blotting (Sun et al. 2016) and for the identification of an ALIX homologue in the sea urchin Paracentrotus lividus (Romancino et al. 2013).
- Species Cross-Reactivity
Target Species Cross Reactivity Human Xenopus Rat Mouse
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide (NaN3)
- Carrier Free
- Alix-GST fusion protein.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Fusion Partners
- Spleen cells from immunized Balb/c mice were fused with cells of the SP2/0 murine myeloma.
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- Q8WUM4 Related reagents
- Entrez Gene
- PDCD6IP Related reagents
- GO Terms
- GO:0006915 apoptosis
- GO:0005829 cytosol
- GO:0005815 microtubule organizing center
- GO:0007049 cell cycle
- GO:0015031 protein transport
- GO:0042470 melanosome
- GO:0044419 interspecies interaction between organisms
- GO:0048306 calcium-dependent protein binding
- GO:0051301 cell division
- For research purposes only
Applications of ALIX antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Paraffin|
- This product does not require protein digestion pre-treatment of paraffin sections.
Secondary Antibodies Available
Application Based External Images
Product Specific References
Pan, S. et al. (2006) Involvement of the conserved adaptor protein Alix in actin cytoskeleton assembly.
J Biol Chem. 281 (45): 34640-50.
References for ALIX antibody
Pan, S. et al. (2008) Extracellular Alix regulates integrin-mediated cell adhesions and extracellular matrix assembly.
EMBO J. 27: 2077-90.
Dangaj, D. et al. (2011) Mannose Receptor (MR) Engagement by Mesothelin GPI Anchor Polarizes Tumor-Associated Macrophages and Is Blocked by Anti-MR Human Recombinant Antibody.
PLoS One. 6: e28386.
Liu, W. et al. (2012) Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration.
J Invest Dermatol. 132 (12): 2828-37.
Zhou, X. et al. (2008) The HIV-1 p6/EIAV p9 docking site in Alix is autoinhibited as revealed by a conformation-sensitive anti-Alix monoclonal antibody.
Biochem J. 414: 215-20.
Pusic, A.D. & Kraig, R.P. (2014) Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination.
Glia. 62 (2): 284-99.
Chen, H.Y. et al. (2009) Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse.
Proc Natl Acad Sci U S A. 106 (34): 14496-501.
Pusic AD et al. (2014) IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
J Neuroimmunol. 266 (1-2): 12-23.
Pusic, A.D. & Kraig, R.P. (2015) Phasic Treatment with Interferon Gamma Stimulates Release of Exosomes that Protect Against Spreading Depression.
J Interferon Cytokine Res. 35 (10): 795-807.
Sun, S. et al. (2016) Phosphorylation-Dependent Activation of the ESCRT Function of ALIX in Cytokinetic Abscission and Retroviral Budding.
Dev Cell. 36 (3): 331-43.
Sun, S. et al. (2015) ALG-2 activates the MVB sorting function of ALIX through relieving its intramolecular interaction.
Cell Discov. 1: 15018.
Feng, Z. et al. (2007) Alternative polyadenylation produces two major transcripts of Alix.
Arch Biochem Biophys. 465 (2): 328-35.